1-20 of 22
Afshin Dowlati
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies

Nehal J. Lakhani, Kyriakos P. Papadopoulos, Melissa Lynne Johnson, Haeseong Park, Ding Wang, Timothy A. Yap, Afshin Dowlati, Robert G. Maki, Susanna Ulahannan, Filipa Lynce, Karen Kelly, Stephen Williamson, Jyoti Malhotra, Shuquan Chen, Ana Gonzalez Ortiz, Vladimir Jankovic, Anne Paccaly, Sheila Masinde, Jayakumar Mani, Israel Lowy, Giuseppe Gullo, Tasha Sims, Glenn Kroog
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (24): 5601–5611.
https://doi.org/10.1158/1078-0432.CCR-23-3883
Published: 16 December 2024
View article titled, First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies
Open the PDF for First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies in another window
Includes: Supplementary data
Journal Articles

A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer

Daniel Morgensztern, Neal Ready, Melissa L. Johnson, Afshin Dowlati, Noura Choudhury, David P. Carbone, Eric Schaefer, Susanne M. Arnold, Sonam Puri, Zofia Piotrowska, Aparna Hegde, Anne C. Chiang, Wade Iams, Anthony Tolcher, Kaname Nosaki, Toshiyuki Kozuki, Tianhong Li, Rafael Santana-Davila, Hiroaki Akamatsu, Haruyasu Murakami, Hiroshi Yokouchi, Song Wang, Jiuhong Zha, Rui Li, Randy R. Robinson, Pooja Hingorani, Edwin E. Jeng, Muhammad Furqan
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (22): 5042–5052.
https://doi.org/10.1158/1078-0432.CCR-24-1547
Published: 15 November 2024
View article titled, A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
Open the PDF for A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed–Platinum–Radiation in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer: Results of a Phase I Trial

Tithi Biswas, Afshin Dowlati, Charles A. Kunos, John J. Pink, Nancy L. Oleinick, Shakun Malik, Pingfu Fu, Shufen Cao, Debora S. Bruno, David L. Bajor, Monaliben Patel, Stanton L. Gerson, Mitchell Machtay
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 646–652.
https://doi.org/10.1158/1078-0432.CCR-21-2025
Published: 15 February 2022
View article titled, Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed–Platinum–Radiation in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer: Results of a Phase I Trial
Open the PDF for Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed–Platinum–Radiation in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer: Results of a Phase I Trial in another window
Includes: Supplementary data
Journal Articles

Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

Roisin M. Connolly, Eric Laille, Ulka Vaishampayan, Vincent Chung, Karen Kelly, Afshin Dowlati, Olatunji B. Alese, R. Donald Harvey, Paul Haluska, Lillian L. Siu, Shivaani Kummar, Richard Piekarz, S. Percy Ivy, Nicole M. Anders, Melinda Downs, Ashley O'Connor, Angela Scardina, Jacqueline Saunders, Gary L. Rosner, Michael A. Carducci, Michelle A. Rudek
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5329–5337.
https://doi.org/10.1158/1078-0432.CCR-20-1412
Published: 15 October 2020
View article titled, Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Open the PDF for Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study in another window
Journal Articles

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study

Daniel Morgensztern, Benjamin Besse, Laurent Greillier, Rafael Santana-Davila, Neal Ready, Christine L. Hann, Bonnie S. Glisson, Anna F. Farago, Afshin Dowlati, Charles M. Rudin, Sylvestre Le Moulec, Satwant Lally, Sreeni Yalamanchili, Jürgen Wolf, Ramaswamy Govindan, David P. Carbone
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (23): 6958–6966.
https://doi.org/10.1158/1078-0432.CCR-19-1133
Published: 02 December 2019
View article titled, Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study
Open the PDF for Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study in another window
Includes: Supplementary data
Journal Articles

Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target

Vadim S. Koshkin, Jorge A. Garcia, Jordan Reynolds, Paul Elson, Cristina Magi-Galluzzi, Jesse K. McKenney, Kumiko Isse, Evan Bishop, Laura R. Saunders, Aysegul Balyimez, Summya Rashid, Ming Hu, Andrew J. Stephenson, Amr F. Fergany, Byron H. Lee, Georges-Pascal Haber, Afshin Dowlati, Timothy Gilligan, Moshe C. Ornstein, Brian I. Rini, Mohamed E. Abazeed, Omar Y. Mian, Petros Grivas
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (1): 210–221.
https://doi.org/10.1158/1078-0432.CCR-18-1278
Published: 03 January 2019
View article titled, Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target
Open the PDF for Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target in another window
Includes: Supplementary data
Journal Articles

A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors

Afshin Dowlati, Gordana Vlahovic, Ronald B. Natale, Erik Rasmussen, Indrajeet Singh, Yuying C. Hwang, John Rossi, Michael B. Bass, Gregory Friberg, Cheryl A. Pickett
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (18): 4574–4584.
https://doi.org/10.1158/1078-0432.CCR-15-2145
Published: 15 September 2016
View article titled, A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Low PIAS3 Expression in Malignant Mesothelioma Is Associated with Increased STAT3 Activation and Poor Patient Survival

Snehal Dabir, Amy Kluge, Adam Kresak, Michael Yang, Pingfu Fu, Bernd Groner, Gary Wildey, Afshin Dowlati
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (19): 5124–5132.
https://doi.org/10.1158/1078-0432.CCR-14-1233
Published: 30 September 2014
View article titled, Low PIAS3 Expression in Malignant Mesothelioma Is Associated with Increased STAT3 Activation and Poor Patient Survival
Open the PDF for Low PIAS3 Expression in Malignant Mesothelioma Is Associated with Increased STAT3 Activation and Poor Patient Survival in another window
Journal Articles

Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

Stephen I. Shibata, Vincent Chung, Timothy W. Synold, Jeffrey A. Longmate, A. Benjamin Suttle, Lone H. Ottesen, Heinz-Josef Lenz, Shivaani Kummar, R. Donald Harvey, Anne L. Hamilton, Bert H. O'Neil, John Sarantopoulos, Patricia LoRusso, Michelle A. Rudek, Afshin Dowlati, Daniel L. Mulkerin, Chandra P. Belani, Leena Gandhi, S. Cecilia Lau, S. Percy Ivy, Edward M. Newman
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (13): 3631–3639.
https://doi.org/10.1158/1078-0432.CCR-12-3214
Published: 30 June 2013
View article titled, Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Open the PDF for Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study in another window
Includes: Supplementary data
Journal Articles

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432

Patricia M. LoRusso, Karthik Venkatakrishnan, Ramesh K. Ramanathan, John Sarantopoulos, Daniel Mulkerin, Stephen I. Shibata, Anne Hamilton, Afshin Dowlati, Sridhar Mani, Michelle A. Rudek, Chris H. Takimoto, Rachel Neuwirth, Dixie-Lee Esseltine, Percy Ivy
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10): 2954–2963.
https://doi.org/10.1158/1078-0432.CCR-11-2873
Published: 14 May 2012
View article titled, Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432
Open the PDF for Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432 in another window
Journal Articles

Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer

Helen J. Ross, George R. Blumenschein,, Jr., Joseph Aisner, Nevena Damjanov, Afshin Dowlati, Jennifer Garst, James R. Rigas, Michael Smylie, Habib Hassani, Kimberly E. Allen, Lance Leopold, Tal Z. Zaks, Frances A. Shepherd
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (6): 1938–1949.
https://doi.org/10.1158/1078-0432.CCR-08-3328
Published: 14 March 2010
View article titled, Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer
Open the PDF for Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Pelvic Radiation, Weekly Cisplatin, and 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, NSC #663249) for Locally Advanced Cervical Cancer

Charles A. Kunos, Steven Waggoner, Vivian von Gruenigen, Elisa Eldermire, John Pink, Afshin Dowlati, Timothy J. Kinsella
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (4): 1298–1306.
https://doi.org/10.1158/1078-0432.CCR-09-2469
Published: 15 February 2010
View article titled, Phase I Trial of Pelvic Radiation, Weekly Cisplatin, and 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, NSC #663249) for Locally Advanced Cervical Cancer
Open the PDF for Phase I Trial of Pelvic Radiation, Weekly Cisplatin, and 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, NSC #663249) for Locally Advanced Cervical Cancer in another window
Journal Articles

A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors

Brian I. Rini, Jorge A. Garcia, Matthew M. Cooney, Paul Elson, Allison Tyler, Kristi Beatty, Joseph Bokar, Tarek Mekhail, R.M. Bukowski, G. Thomas Budd, Pierre Triozzi, Ernest Borden, Percy Ivy, Helen X. Chen, Afshin Dowlati, Robert Dreicer
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (19): 6277–6283.
https://doi.org/10.1158/1078-0432.CCR-09-0717
Published: 30 September 2009
View article titled, A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors
Open the PDF for A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors in another window
Journal Articles

Phase I Trial of Pazopanib in Patients with Advanced Cancer

Herbert I. Hurwitz, Afshin Dowlati, Shermini Saini, Shawna Savage, A. Benjamin Suttle, Diana M. Gibson, Jeffrey P. Hodge, Elmar M. Merkle, Lini Pandite
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (12): 4220–4227.
https://doi.org/10.1158/1078-0432.CCR-08-2740
Published: 15 June 2009
View article titled, Phase I Trial of Pazopanib in Patients with Advanced Cancer
Open the PDF for Phase I Trial of Pazopanib in Patients with Advanced Cancer in another window
Journal Articles

A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers

Joseph Baar, Paula Silverman, Janice Lyons, Pingfu Fu, Fadi Abdul-Karim, Nicholas Ziats, Jay Wasman, Paul Hartman, John Jesberger, Leda Dumadag, Erin Hohler, Rosemary Leeming, Robert Shenk, Helen Chen, Keith McCrae, Afshin Dowlati, Scot C. Remick, Beth Overmoyer
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (10): 3583–3590.
https://doi.org/10.1158/1078-0432.CCR-08-2917
Published: 18 May 2009
View article titled, A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers
Open the PDF for A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers in another window
Journal Articles

Confirmation of Gene Expression–Based Prediction of Survival in Non–Small Cell Lung Cancer

Nancy L. Guo, Ying-Wooi Wan, Kursad Tosun, Hong Lin, Zola Msiska, Daniel C. Flynn, Scot C. Remick, Val Vallyathan, Afshin Dowlati, Xianglin Shi, Vincent Castranova, David G. Beer, Yong Qian
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (24): 8213–8220.
https://doi.org/10.1158/1078-0432.CCR-08-0095
Published: 15 December 2008
View article titled, Confirmation of Gene Expression–Based Prediction of Survival in Non–Small Cell Lung Cancer
Open the PDF for Confirmation of Gene Expression–Based Prediction of Survival in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study

Afshin Dowlati, Robert Gray, Alan B. Sandler, Joan H. Schiller, David H. Johnson
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (5): 1407–1412.
https://doi.org/10.1158/1078-0432.CCR-07-1154
Published: 03 March 2008
View article titled, Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study
Open the PDF for Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study in another window
Includes: Supplementary data
Journal Articles

Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin

Beth Overmoyer, Pingfu Fu, Charles Hoppel, Tomas Radivoyevitch, Robert Shenk, Marjie Persons, Paula Silverman, Kelly Robertson, Nicholas P. Ziats, Jay K. Wasman, Fadi W. Abdul-Karim, John A. Jesberger, Jeffrey Duerk, Paul Hartman, Shelli Hanks, Jonathan Lewin, Afshin Dowlati, Keith McCrae, Percy Ivy, Scot C. Remick
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19): 5862–5868.
https://doi.org/10.1158/1078-0432.CCR-07-0688
Published: 01 October 2007
View article titled, Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin
Open the PDF for Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin in another window
Journal Articles

Novel Phase I Dose De-escalation Design Trial to Determine the Biological Modulatory Dose of the Antiangiogenic Agent SU5416

Afshin Dowlati, Kelly Robertson, Tomas Radivoyevitch, John Waas, Nicholas P. Ziats, Paul Hartman, Fadi W. Abdul-Karim, Jay K. Wasman, Jack Jesberger, Jonathan Lewin, Keith McCrae, Percy Ivy, Scot C. Remick
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7938–7944.
https://doi.org/10.1158/1078-0432.CCR-04-2538
Published: 08 November 2005
View article titled, Novel Phase I Dose De-escalation Design Trial to Determine the Biological Modulatory Dose of the Antiangiogenic Agent SU5416
Open the PDF for Novel Phase I Dose De-escalation Design Trial to Determine the Biological Modulatory Dose of the Antiangiogenic Agent SU5416 in another window
Journal Articles

Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced Cancer

Matthew M. Cooney, Tomas Radivoyevitch, Afshin Dowlati, Beth Overmoyer, Nathan Levitan, Kelly Robertson, Sandra L. Levine, Kathleen DeCaro, Carol Buchter, Anne Taylor, Bruce S. Stambler, Scot C. Remick
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (1): 96–100.
https://doi.org/10.1158/1078-0432.CCR-0364-3
Published: 20 January 2004
View article titled, Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced Cancer
Open the PDF for Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced Cancer in another window